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116 Poster Session-IIPatients with cGVHD had significantly higher BAFF:B cell ratios
and fewer circulating IgD1CD38LoCD27- (naive) and
IgD1CD38HiCD27- (transitional) B cells compared to patients
without cGVHD. All HSCT patient groups had elevated BAFF
levels but patients without cGVHDhad supranormal numbers of na-
ive and transitional B cells resulting in normal BAFF:B cell ratios.
This suggests that increased numbers of naive B cells in patients
without cGVHD reflect a normal B cell homeostatic compensatory
mechanism. Patients with cGVHDhad fewer B cells, but unlike nor-
mal CD271 antigen-experienced B cells, CD271 B cells from
cGVHD patients were in vivo activated and capable of IgG produc-
tion without additional antigen or second signal stimulation. Serial
measurements of BAFF and B cell subsets in a second series of 25 pa-
tients followed for 1 year post-HSCT revealed high BAFF levels as-
sociated with B cell lymphopenia in all patients early post-HSCT.
Following autologous HSCT (n5 8) BAFF levels decreased rapidly
as B cell numbers recovered after transplant. In patients without
cGVHD (n5 8), BAFF levels also decreased as peripheral B cells re-
constituted. In contrast, patients who developed cGVHD (n 5 17)
had persistently elevated BAFF levels. In these patients, elevated
BAFF levels were associated with delayed reconstitution of naive B
cells and proportional increases in antigen-experienced CD271 B
cells in the first year post-HSCT.These studies demonstrate distinct
abnormalities in B cell homeostasis associated with excess BAFF in
patients with cGVHD and begin to delineate mechanisms of B cell
pathophysiology in these patients. BAFF appears to play a critical
role in the maintenance of functionally activated B cells after
HSCT and BAFF targeting agents may be useful in the treatment
of cGVHD.323
FEMALE DONOR H-Y SEROPOSITIVITY DOES NOT PREDICT MALE RECIP-
IENT HCT OUTCOMES, INCLUDING CGVHD
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Following HLA-identical hematopoietic cell transplantation
(HCT), T and B cells target minor histocompatibility antigens
(mHA) providing beneficial GVL and detrimental GVHD. Males
who have undergone sex-mismatched allogeneic HCT (F/M) ex-
perience more GVHD and less disease relapse compared to any
other donor and recipient gender combination. Y chromosome en-
coded mHA, H-Y antigens, are frequently recognized by T and B
cells following F/MHCT. Earlier, we developed ELISA for 5 H-
Y antigens (DDX3Y, UTY, RPS4Y1, ZFY, and EIF1AY), and
showed 50% of F/M HCT patients develop specific antibodies
for any of these H-Y antigens 4–12 months after HCT. H-Y anti-
body develops in association with cGVHD and persistent disease
remission (p\0.0001). In addition, 30% of females have low-titer
H-Y antibodies, while males have no antibodies. Here, we study
whether preexisting H-Y antibodies in female donors predict
male recipient cGVHD or relapse and overall survival. In collabo-
ration with the NMDP and CIBMTR, pretransplant sera were col-
lected from 289 female donors who donated unrelated bone
marrow for HLA-identical male recipients undergoing myeloabla-
tive HCT for AML(18%), CML(38%), ALL(24%), MDS(13%),
and NHL(7%). Primary immune prophylaxis was CSA/ FK506
plus MTX (78%) and T Cell depletion (22%). With eight year me-
dian follow-up, cGVHD incidence was 47%, 18% relapsed, and
overall survival was 50.2% at one year and 41.8% at two years.
22.3% female donor sera tested positive for any H-Y antigen by
ELISA. To test for alternative antigen presentation chemistry,
H-Y antigens were also printed onto nitrocellulose microarrays at
0.1 mg/ml, incubated with sera and H-Y specific antibody was de-
tected with anti hIgG. H-Y microarrays detected antibodies for
any H-Y antigen in 33% of female donors. H-Y seropositivity
did not correlate with donor age by quartile. H-Y seropositivity
did not correlate with the reported number of donor pregnancies:
nulliparous (38%), one (16%), two (19%), and three or more
(26%). Male recipients of H-Y seropositive donors had 51.2%
cGVHD incidence, 20.1% relapse, and 45.8% overall survival at
2 years. By Cox regression analysis, these clinical outcomes for
seronegative donors did not differ significantly: 42.7% cGVHD,
17.8% relapse, and 39.3% overall survival. Testing for H-Yantibodies in female donors before sex-mismatched HCT will not
predict cGVHD or relapse risk suggesting cGVHD and GVL
responses develop from naı¨ve and not memory lymphocytes.324
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Vaccinations are generally performed to enhance alloantigen spe-
cific immune responses. However, whether it can be utilized to
dampen alloantigen specific immune responses is not known. There-
fore, we tested the hypothesis that vaccination of donors with host-
derived CD8a1 dendritic cells (DCs), which are known to be tolero-
genic, will reduce host-specific donor T cell responses. We vacci-
nated donor (BALB/c) mice with host (B6) bone marrow (BM)
derived CD8a1DCs. Both unvaccinated donors and those vacci-
nated with CD8a- DCs served as controls. BM derived DCs were
sorted for CD11c1CD8a1 or CD11c1CD8a- DCs. CD8a1 and
CD8a- DCs were injected into donors and T cells were harvested.
BALB/c T cells from the B6 CD8a1DC vaccinated mice (hereafter
referred to as CD8a1DC Tvac) demonstrated significantly reduced
proliferation, secretion of IL-2 and IFN-g but greater secretion of
IL-10 in an MLR with B6 DCs when compared with T cells from
non-vaccinated and CD8a- DCs vaccinated mice. By contrast they
demonstrated equivalent proliferation when stimulated with DCs
from a third party (C3HHEJ) demonstrating loss of only antigen
specific responses. The reduction in allo-antigen responses by the
CD8a1DC Tvac cells was also not apparent with T cells from
IL-10 deficient donors, demonstrating a functional relevance for
IL-10. We next evaluated the impact of CD8a1DC Tvac cells in
a clinically relevant model of GVHD. Recipient (B6) mice were le-
thally irradiated and transplanted on day 0 with TCD BM from syn-
geneic (B6) or allogeneic (BALB/c) donors along with 4 106 T cells
from either unvaccinated or B6 BM CD8a1 DC or CD8-DC Tvac
cells from allogeneic (BALB/c) donors. Recipients of CD8a1 DC
Tvac demonstrated significantly better survival (70% vs 0%,
p\0.001) and reduced clinical and histopathological severity of
GVHD when compared with the allogeneic controls. Post-BMT
analyses demonstrated, consistent in vitro, significantly less donor
T cell proliferation, higher serum levels of IL-10 and reduced levels
of TNF-a and IFN-g when compared with the allogeneic controls.
By contrast vaccination of IL-10KO (B6) with BALB/cCD8a1DCs
did not reduce GVHD after B6/BALB/c BMT demonstrating
a critical role for IL-10 in CD8a1DC vaccination mediated protec-
tion. In conclusion, host CD8a1DC vaccination of donors reduces
allo-antigen specific responses in vitro and GVHD severity in vivo.
Thus, vaccination strategies might be employed to reduce undesired
immune responses.325
IMPACT OF CYCLOSPORINE A (CSA) CONCENTRATION ON THE INCI-
DENCE OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
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Previous studies have demonstrated that the immunosuppressive
effects of CsA (eg. inhibition of calcineurine in lymphocytes) may
be correlated with CsA blood concentration, especially in the con-
text of solid organ transplantation. This report investigated the
impact of CsA concentrations in the early post allo-SCT period,
on the incidence of severe acute GVHD, in 85 consecutive pa-
tients treated in a single centre between Jan. 2006 and Jan.
2008, and for whom CsA concentrations in the blood were mon-
itored weekly. 85 patients received CsA (usually at 3 mg/Kg/d, 2
or 3 d. prior to graft infusion) as a 24-h continuous infusion until
hematopoietic recovery and switch to oral formulation. Dose
modifications of CsA were performed to maintain adequate
trough blood levels and to prevent nephrotoxicity. Median age
